News Moderna shines spotlight on new flu vaccine data Moderna may be facing regulatory uncertainty in the US for its vaccine pipeline, but at least its clinical data is hitting the right notes.
News Moderna's RSV shot gets US nod for use in younger adults The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?
News Moderna's $760m-plus flu vaccine contracts are nixed by HHS HHS cancels funding for Moderna's pandemic flu vaccine development in a move viewed by some as an attack on mRNA technology.
News FDA tightens heart tox warnings on mRNA COVID vaccines The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity.
News There's good news for RSV jab firms at delayed ACIP meeting GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.
News GSK rides out vaccine sales weakness with cancer, HIV gains Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face